Article Information
History
- May 24, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Laty G. Thiam1,
- Kirsty McHugh2,
- Aboubacar Ba1,
- Rebecca Li3,
- Yicheng Guo4,
- Mariama N. Pouye1,
- Awa Cisse3,
- Dimitra Pipini2,
- Fatoumata Diallo1,
- Seynabou D. Sene1,
- Saurabh D. Patel1,
- Alassane Thiam1,
- Bacary D. Sadio5,
- Alassane Mbengue1,
- Inés Vigan-Womas1,
- Zizhang Sheng4,
- Lawrence Shapiro4,6,
- Simon J. Draper2,7 and
- Amy K. Bei1,3,*
- 1G4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
- 2Department of Biochemistry and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
- 3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
- 4Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
- 5Pôle Virologie, Institut Pasteur de Dakar, Dakar, Senegal.
- 6Department of Biochemistry and Biophysics, Columbia University, New York, NY, USA.
- 7NIHR Oxford Biomedical Research Centre, Oxford, UK.
- ↵*Corresponding author; email: amy.bei{at}yale.edu
Posted May 24, 2024.
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates
